04 August, 2017
07/27/2017 - Boston Scientific Corporation had its " rating reiterated by analysts at Stifel Nicolaus. Corporate insiders own 42.03% of the company's stock.
Other large investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in Boston Scientific Corporation by 10.3% in the first quarter. FMR LLC boosted its position in Boston Scientific by 7.6% in the first quarter. Over the last three months, insiders sold 192,850 shares of company stock worth $7,281,691. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Boston Scientific Corporation during the first quarter valued at about $215,000. SG Americas Securities LLC bought a new position in Scientific Games Corp during the first quarter worth about $130,000.
As of the end of the quarter First Trust Advisors Lp had disposed of a total of 83,131 shares trimming its stake by 46.0%. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider's stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the period.
When completing stock analysis, investors and traders may opt to review other technical levels. On Tuesday, February 28 Mirviss Jeffrey B. sold $616,663 worth of Boston Scientific Corporation (NYSE:BSX) or 25,000 shares. BSX exchanged 6.32 million shares in recent session versus to the average volume of 6.33 million shares while its relative volume is 1.00.
Boston Scientific Corporation has a 50 day moving average of 27.64 and a 200 day moving average of 25.93. The firm's stock has a market capitalization of $36.32 bln. Heritage Mgmt Corp invested 0.09% of its portfolio in Boston Scientific Corporation (NYSE:BSX). A month ago, analyst EPS consensus estimated earnings of US$0.31 per share.
21 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 2327.73 million while high and low sale targets are estimated at 2384 million and 2299 million respectively. During the same period in the prior year, the business posted ($0.59) earnings per share. The firm's revenue was up 6.2% on a year-over-year basis. On average, equities research analysts anticipate that Scientific Games Corp will post ($2.27) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: "Boston Scientific Co". (NYSE BSX) opened at 26.51 on Thursday. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & global trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/08/03/scientific-games-corp-sgms-releases-earnings-results-beats-estimates-by-0-07-eps-updated.html.
M are held by Fine Prtn L P. Gabelli Funds Limited reported 0.03% of its portfolio in Scientific Games Corp (NASDAQ:SGMS). Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 price objective (up from $29.00) on shares of Boston Scientific Corporation in a research note on Thursday, April 27th. The stock of Boston Scientific Corporation (NYSE:BSX) earned "Hold" rating by Oppenheimer on Wednesday, June 28. Analysts on average have given a price target of $30.59 to Boston Scientific Corporation stock. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The company now has an average rating of "Hold" and an average target price of $30.00. Also, EVP James C. Kennedy sold 122,681 shares of the stock in a transaction that occurred on Monday, July 31st. Geduld E E sold 50,000 shares as Boston Scientific Corp (Call) (BSX)'s stock rose 4.02%. Following the completion of the transaction, the executive vice president now directly owns 195,846 shares of the company's stock, valued at approximately $5,223,212.82.
In related news, Director Gabrielle K. Mcdonald sold 2,133 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $28.02, for a total value of $434,310.00. The disclosure for this sale can be found here. Another trade for 154,951 shares valued at $3.53 million was made by Isaacs Michael Gavin on Tuesday, May 2. Guggenheim Cap Limited Company reported 18,969 shares or 0% of all its holdings. Boston Scientific Corp (BSX)'s Williams %R presently stands at -72.53. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
